Publicaciones científicas
Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score
Borja Rivero-Santana 1 , Jesús Saldaña-García 1 , Juan Caro-Codón 1 , Pilar Zamora 2 , Pedro Moliner 3 , Amparo Martínez Monzonis 4 , Eduardo Zatarain 5 , Carlos Álvarez-Ortega 1 , Pilar Gómez-Prieto 6 , Sonia Pernas 7 , Isabel Rodriguez 8 , Antonio Buño Soto 9 , Rosalía Cadenas 10 , Patricia Palacios Ozores 11 , Sara Pérez Ramírez 12 , María Merino Salvador 13 , Silvia Valbuena 1 , Lucía Fernández Gasso 1 , Victor Juárez 14 , Andrea Severo 14 , Belén Terol 15 , Teresa de Soto Álvarez 6 , Olaia Rodríguez 9 , María Brion 4 , José González-Costello 3 , Miguel Canales Albendea 16 , José R González-Juanatey 4 , Raúl Moreno 1 , José López-Sendón 17 , Teresa López-Fernández 1 15
Background and aims: Baseline cardiovascular toxicity risk stratification is critical in cardio-oncology. The Heart Failure Association (HFA) and International Cardio-Oncology Society (ICOS) score aims to assess this risk but lacks real-life validation. This study validates the HFA-ICOS score for anthracycline-induced cardiovascular toxicity.
Methods: Anthracycline-treated patients in the CARDIOTOX registry (NCT02039622) were stratified by the HFA-ICOS score. The primary endpoint was symptomatic or moderate to severe asymptomatic cancer therapy-related cardiac dysfunction (CTRCD), with all-cause mortality and cardiovascular mortality as secondary endpoints.
Results: The analysis included 1066 patients (mean age 54 ± 14 years; 81.9% women; 24.5% ≥65 years). According to the HFA-ICOS criteria, 571 patients (53.6%) were classified as low risk, 333 (31.2%) as moderate risk, 152 (14.3%) as high risk, and 10 (0.9%) as very high risk. Median follow-up was 54.8 months (interquartile range 24.6-81.8). A total of 197 patients (18.4%) died, and 718 (67.3%) developed CTRCD (symptomatic: n = 45; moderate to severe asymptomatic: n = 24; and mild asymptomatic: n = 649). Incidence rates of symptomatic or moderate to severe symptomatic CTRCD and all-cause mortality significantly increased with HFA-ICOS score [hazard ratio 28.74, 95% confidence interval (CI) 9.33-88.5; P < .001, and hazard ratio 7.43, 95% CI 3.21-17.2; P < .001) for very high-risk patients. The predictive model demonstrated good calibration (Brier score 0.04, 95% CI 0.03-0.05) and discrimination (area under the curve 0.78, 95% CI 0.70-0.82; Uno's C-statistic 0.78, 95% CI 0.71-0.84) for predicting symptomatic or severe/moderate asymptomatic CTRCD at 12 months.
Conclusions: The HFA-ICOS score effectively categorizes patients by cardiovascular toxicity risk and demonstrates strong predictive ability for high-risk anthracycline-related cardiovascular toxicity and all-cause mortality.
CITA DEL ARTÍCULO Eur Heart J. 2024 Aug 6:ehae496. doi: 10.1093/eurheartj/ehae496
Nuestros autores
